Detalles de la búsqueda
1.
Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Blood
; 140(22): 2348-2357, 2022 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35921541
2.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Hematol Oncol
; 42(1): e3216, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37772620
3.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287529
4.
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs.
Blood
; 137(25): 3507-3517, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33651883
5.
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy.
Haematologica
; 108(8): 2101-2115, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36655432
6.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36632738
7.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Hematol Oncol
; 41(5): 877-883, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37392141
8.
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
Curr Opin Oncol
; 34(6): 757-767, 2022 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35993294
9.
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group.
Hematol Oncol
; 39(3): 326-335, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33739461
10.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33378569
11.
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.
Haematologica
; 105(4): 1042-1054, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31289209
12.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.
Haematologica
; 105(2): 448-456, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31371416
13.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol
; 95(6): 604-611, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32096887
14.
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Am J Hematol
; 99(5): 982-984, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38343033
15.
B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide.
Blood
; 137(16): 2267-2271, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33512465
16.
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Haematologica
; 103(7): 1209-1217, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29674504
17.
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia.
Hematol Oncol
; 2018 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29602219
18.
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia.
Hematol Oncol
; 41(3): 567-570, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36190298
19.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Am J Hematol
; 98(9): E237-E240, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382471
20.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36349541